ReviewExperimental biology and medicine (Maywood, N.J.)2016
The use of CD47-modified biomaterials to mitigate the immune response.
Review in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A Hybrid Mesenchymal-Stem-Cell-Derived Decellularized Matrix Scaffold Supports Bone Repair and Vascular Perfusion in Steroid-Associated Osteonecrosis.Biomaterials research · 2026Article
- Advances and applications in medical coating materials: a comprehensive review.Frontiers in chemistry · 2026Review
- Platelets: the first cellular responders in the foreign body response to blood-contacting biomaterials.Frontiers in immunology · 2026Review
- Microencapsulation-based cell therapies.Cellular and molecular life sciences : CMLS · 2022Review
- Metallic Nanoparticle-Mediated Immune Cell Regulation and Advanced Cancer Immunotherapy.Pharmaceutics · 2021Review
- Camouflage strategies for therapeutic exosomes evasion from phagocytosis.Journal of advanced research · 2021Review
- Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization.Journal of visualized experiments : JoVE · 2020Article
- Interactions at engineered graft-tissue interfaces: A review.APL bioengineering · 2020Review
- Studies of combined NO-eluting/CD47-modified polyurethane surfaces for synergistic enhancement of biocompatibility.Colloids and surfaces. B, Biointerfaces · 2020Article
- Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Zwitterionic polymer/polydopamine coating reduce acute inflammatory tissue responses to neural implants.Biomaterials · 2019Article
- Thrombospondin-1, Free Radicals, and the Coronary Microcirculation: The Aging Conundrum.Antioxidants & redox signaling · 2017Review
- Effects of aging upon the host response to implants.Journal of biomedical materials research. Part A · 2017Article
- Effects of age-related shifts in cellular function and local microenvironment upon the innate immune response to implants.Seminars in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Addressing the aberrant interactions between immune cells and biomaterials represents an unmet need in biomaterial research. Although progress has been made in the development of bioinert coatings, identifying and targeting relevant cellular and molecular pathways can provide additional therapeutic strategies to address this major healthcare concern. To that end, we describe the immune inhibitory motif, receptor-ligand pairing of signal regulatory protein alpha and its cognate ligand CD47 as a potential signaling pathway to enhance biocompatibility. The goals of this article are to detail the known roles of CD47-signal regulatory protein alpha signal transduction pathway and to describe how immobilized CD47 can be used to mitigate the immune response to biomaterials. Current applications of CD47-modified biomaterials will also be discussed herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.